Gritstone Bio Inc

NASDAQ:GRTS   3:59:57 PM EDT
6.25
-0.05 (-0.79%)
Products

Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study Evaluating a T Cell-Enhanced Self-Amplifying mRNA Vaccine Against COVID-19

Published: 01/04/2022 12:21 GMT
Gritstone Bio Inc (GRTS) - Gritstone Announces Positive Clinical Results From First Cohort of a Phase 1 Study (coral-boost) Evaluating a T Cell-enhanced Self-amplifying Mrna (samrna) Vaccine Against Covid-19.
Gritstone Bio Inc - Samrna Vaccine Was Well-tolerated in These Subjects, With No Grade 3 Or 4 Adverse Events Observed.
Gritstone Bio Inc - Gritstone is Expanding Coral-boost to 120 Subjects.
Gritstone - Data From First Cohort of Coral-boost Study Showed Both Strong Neutralizing Antibody Responses to Spike and Robust Cd8+ T Cell Responses.
Gritstone Bio Inc - Samrna Vaccine Elicited Broad Cd8+ T Cell Responses Against Conserved Non-spike Sars-cov-2 Epitopes.
Gritstone Bio Inc - Samrna Vaccine Boosted Pre-existing Spike-specific T Cells.